US President Donald Trump’s recent announcement to cut the cost of prescription drugs has jolted Indian and APAC manufacturers. While this new development comes a few months after the initial pharma tariff move, Indian pharmaceutical companies aren’t left with much choice except to strategise their next steps pragmatically. Our Partner Ravi Shah shares his views on this in an article published by BioSpectrum India. (Photo Credits: BioSpectrum India)
